In this context, the target of Mogamulizumab, CCR4, is not only highly expressed on neoplastic T lymphocytes of MF and SS but also on T-helper 2 (Th2) and regulatory T-cells (Tregs) [13], playing a pivotal physiological role. This evidence concerns the gene CCR4 and synovial sarcoma.